These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 19917123)

  • 1. Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma.
    Susa M; Iyer AK; Ryu K; Hornicek FJ; Mankin H; Amiji MM; Duan Z
    BMC Cancer; 2009 Nov; 9():399. PubMed ID: 19917123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effective combination therapy against human osteosarcoma: doxorubicin plus curcumin co-encapsulated lipid-coated polymeric nanoparticulate drug delivery system.
    Wang L; Wang W; Rui Z; Zhou D
    Drug Deliv; 2016 Nov; 23(9):3200-3208. PubMed ID: 26987435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma.
    Susa M; Iyer AK; Ryu K; Choy E; Hornicek FJ; Mankin H; Milane L; Amiji MM; Duan Z
    PLoS One; 2010 May; 5(5):e10764. PubMed ID: 20520719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of tumor-targeting peptide-decorated polypeptide nanoparticles with doxorubicin to treat osteosarcoma.
    Qiu R; Sun D; Bai Y; Li J; Wang L
    Drug Deliv; 2020 Nov; 27(1):1704-1717. PubMed ID: 33305647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy.
    Li Y; Hou H; Zhang P; Zhang Z
    Drug Deliv; 2020 Dec; 27(1):1044-1053. PubMed ID: 32633576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells.
    Duan Z; Zhang J; Ye S; Shen J; Choy E; Cote G; Harmon D; Mankin H; Hua Y; Zhang Y; Gray NS; Hornicek FJ
    BMC Cancer; 2014 Sep; 14():681. PubMed ID: 25236161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondria-targeting graphene oxide nanocomposites for fluorescence imaging-guided synergistic phototherapy of drug-resistant osteosarcoma.
    Zeng WN; Yu QP; Wang D; Liu JL; Yang QJ; Zhou ZK; Zeng YP
    J Nanobiotechnology; 2021 Mar; 19(1):79. PubMed ID: 33740998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925.
    Yang X; Yang P; Shen J; Osaka E; Choy E; Cote G; Harmon D; Zhang Z; Mankin H; Hornicek FJ; Duan Z
    Br J Cancer; 2014 Jun; 110(12):2896-904. PubMed ID: 24853187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional Doxorubicin-Loaded Omega-3 Unsaturated Fatty Acids Nanoparticles in Reversing Hepatocellular Carcinoma Multidrug Resistance.
    Wang C; Wei X; Shao G
    Med Sci Monit; 2021 Feb; 27():e927727. PubMed ID: 33524008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.
    Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y
    J Bone Joint Surg Am; 2000 Jul; 82-A(7):963-9. PubMed ID: 10901311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1® can Overcome Drug Resistance in Osteosarcoma.
    Fanelli M; Hattinger CM; Vella S; Tavanti E; Michelacci F; Gudeman B; Barnett D; Picci P; Serra M
    Curr Cancer Drug Targets; 2016; 16(3):261-74. PubMed ID: 26548759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted osteosarcoma chemotherapy using RGD peptide-installed doxorubicin-loaded biodegradable polymeric micelle.
    Fang Z; Sun Y; Xiao H; Li P; Liu M; Ding F; Kan W; Miao R
    Biomed Pharmacother; 2017 Jan; 85():160-168. PubMed ID: 27930982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming cancer multidrug resistance by codelivery of doxorubicin and verapamil with hydrogel nanoparticles.
    Qin M; Lee YE; Ray A; Kopelman R
    Macromol Biosci; 2014 Aug; 14(8):1106-15. PubMed ID: 24771682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.
    Liu T; Li Z; Zhang Q; De Amorim Bernstein K; Lozano-Calderon S; Choy E; Hornicek FJ; Duan Z
    Oncotarget; 2016 Dec; 7(50):83502-83513. PubMed ID: 27835872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ifosfamide-loaded poly (lactic-co-glycolic acid) PLGA-dextran polymeric nanoparticles to improve the antitumor efficacy in Osteosarcoma.
    Chen B; Yang JZ; Wang LF; Zhang YJ; Lin XJ
    BMC Cancer; 2015 Oct; 15():752. PubMed ID: 26486165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of multidrug-resistance using Valspodar (PSC 833) and doxorubicin in osteosarcoma.
    Cagliero E; Ferracini R; Morello E; Scotlandi K; Manara MC; Buracco P; Comandone A; Baroetto Parisi R; Baldini N
    Oncol Rep; 2004 Nov; 12(5):1023-31. PubMed ID: 15492788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arsenic trioxide inhibits the growth of adriamycin resistant osteosarcoma cells through inducing apoptosis.
    Zhao H; Guo W; Peng C; Ji T; Lu X
    Mol Biol Rep; 2010 Jun; 37(5):2509-15. PubMed ID: 19701692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines.
    Duan Z; Choy E; Harmon D; Yang C; Ryu K; Schwab J; Mankin H; Hornicek FJ
    Mol Cancer Ther; 2009 Aug; 8(8):2122-30. PubMed ID: 19638450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines.
    Ye S; Shen J; Choy E; Yang C; Mankin H; Hornicek F; Duan Z
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):349-56. PubMed ID: 26698867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pluronic-based functional polymeric mixed micelles for co-delivery of doxorubicin and paclitaxel to multidrug resistant tumor.
    Chen Y; Zhang W; Huang Y; Gao F; Sha X; Fang X
    Int J Pharm; 2015 Jul; 488(1-2):44-58. PubMed ID: 25899286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.